.css-1xsl8rf{width:100%;display:-webkit-box;display:-webkit-flex;display:-ms-flexbox;display:flex;-webkit-align-items:center;-webkit-box-align:center;-ms-flex-align:center;align-items:center;position:relative;overflow:hidden;background:var(--alert-bg);-webkit-padding-start:var(--chakra-space-4);padding-inline-start:var(--chakra-space-4);-webkit-padding-end:var(--chakra-space-4);padding-inline-end:var(--chakra-space-4);padding-top:var(--chakra-space-1);padding-bottom:var(--chakra-space-1);--alert-fg:var(--chakra-colors-orange-600);--alert-bg:var(--chakra-colors-orange-100);font-weight:var(--chakra-fontWeights-semibold);padding-left:var(--chakra-space-4);}.chakra-ui-dark .css-1xsl8rf:not([data-theme]),[data-theme=dark] .css-1xsl8rf:not([data-theme]),.css-1xsl8rf[data-theme=dark]{--alert-fg:var(--chakra-colors-orange-200);--alert-bg:rgba(251, 211, 141, 0.16);}@media screen and (min-width: 48em){.css-1xsl8rf{padding-left:var(--chakra-space-8);}}Please enable Javascript to use all features and improve your user experience.

Prof. Dr. Rainer Blasczyk

Redner

23/09/2022
15:15 – 15:25 10 Min. 0 Min.
Sonstiges
Einladung des Tagungspräsidenten 2023 zur DGTI 2023 nach Berlin

Plenarredner

23/09/2022
11:30 – 12:00 30 Min. 0 Min.
Plenarvortrag
PL-3-3
Selective depletion of alloreactive B cells

Further involvements

21/09/2022
15:30 – 15:40 6 Min. 4 Min.
Abstractvortrag
VS-6-4
Extracorporeal therapy with purified granulocyte concentrates in patients with septic shock – Start of the randomized controlled clinical trial ReActIF-ICE
13. Neue Blutprodukte – Neue Anwendungen, 9. Hämotherapie
22/09/2022
13:50 – 14:00 6 Min. 4 Min.
Abstractvortrag
VS-13-3
Long-term Follow up (> 1 year) of Plasma Donors and Patients treated with COVID-19 Convalescent Plasma within the CAPSID trial
19. COVID-19, 9. Hämotherapie
22/09/2022
16:10 – 16:20 6 Min. 4 Min.
Abstractvortrag
VS-16-3
The alloCELL program: Patient monitoring, donor selection and GMP-compliant manufacturing of virus-specific T cells from stem cell, family and third-party T-cell donors
12. Zelltherapie und Gentherapie, 8. Immungenetik: HLA und Transplantationen
22/09/2022
16:20 – 16:30 6 Min. 4 Min.
Abstractvortrag
VS-16-4
Genetically engineered lungs are protected from immune rejection in the absence of immunosuppression
12. Zelltherapie und Gentherapie, 8. Immungenetik: HLA und Transplantationen
22/09/2022
16:40 – 16:45 3 Min. 2 Min.
Poster
PS-3-3
Case report of a patient with a newly detected Bombay phenotype
7. Immunhämatologie und Immunologische Grundlagen
22/09/2022
16:45 – 16:50 3 Min. 2 Min.
Poster
PS-4-5
Antiviral T-cell frequencies in a healthy population: Reference values for evaluating antiviral immune cell profiles in immunocompromised patients and their application during the SARS-CoV-2 pandemic
12. Zelltherapie und Gentherapie, 19. COVID-19